As demand for GLP-1 medications for weight loss surges and drug costs exceed $990 per month, state policymakers wrestle with ...

Thousands of knockoff pens were confiscated by enforcement agents for the UK’s Medicines and Healthcare products Regulatory ...

Pakistan’s healthcare landscape has entered a pivotal phase in the management of diabetes and obesity. For years, advanced ...

What is the ‘golden dose’ and what are the risks? Medical News Today asks four experts to weigh in on the trend of trying to ...

"UK regulators seize illegal weight loss drugs amid global pricing shake-up" was originally created and published by ...

Costco (NASDAQ:COST), the warehouse club best known for its bulk bargains and $1.50 hot dogs, is expanding its pharmacy into ...

Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Hims & Hers is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers.

Britain's medicines regulator said on Friday it had made the world's largest seizure of unlicensed weight-loss medicines, ...

Eli Lilly has signed a licensing deal with Cipla to market its blockbuster weight-loss drug under the brand name Yurpeak in ...